 BOSTON, May 23, 2022 GLOBE NEWSWIRE -- Compass Therapeutics, Inc. Nasdaq: CMPX, a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, is presenting virtually at the 2022 H.C. Wainwright Global Investment Conference, occurring May 23-26th, 2022. 